38 results about "Sodium Deoxycholate" patented technology

The application provides a topical traditional Chinese medicine composition for treating vulvar leukoplakia and a preparation method thereof. The composition is composed of traditional Chinese medicinal materials such as angelica, cortex psoraleae and barks of dictamnus dasycarpus, and a penetration enhancer, an activating agent and a moisturizing agent. The penetration enhancer is composed of soybean lecithin, phosphatidylethanolamine and cholesterol, the activating agent is sodium cholate, sodium deoxycholate and sodium taurocholate, and the moisturizing agent is eucalyptus oil. The drugs are compatible to exert the effects of clearing heat and drying dampness, cooling blood and nourishing yin, activating blood and resolving stasis, warming yang and dispelling cold and supporting healthy qi and tonifying the body resistance. The traditional Chinese medicine composition is prepared through supercritical extraction, micronization treatment, solution preparation and intermittent ultrasonic homogenization. The traditional Chinese medicinal materials are used for treating the etiology, pathogenesis and symptoms of vulvar leukoplakia, the penetration enhancer reduces the skin barrier function, the activating agent enhances the drug activity and permeability, and the moisturizing agent maintains the skin moisture and assists in anti-inflammation. The clinical application effectively relieves the symptoms of patients with vulvar leukoplakia, improves the pathological state of local skin and improves the treatment effect, thereby providing a new effective option for the treatment of vulvar leukoplakia.

The application provides a preparation method and application of a near-infrared two-region fluorescent sensor, and chiral single-walled carbon nanotubes are separated by using a double water phase extraction method; materials in the separation process include deionized water, polyethylene glycol, dextran, sodium dodecyl sulfate, sodium deoxycholate and cholic acid sodium hydrate; the chiral single-walled carbon nanotubes are dispersed and mixed with 4-nitrobenzene tetrafluoroboric acid diazonium salt to obtain the fluorescent sensor; high-purity (6,5)-SWCNT is efficiently and simply separated by using the double water phase extraction technology, the prepared SWCNT-NBD nanomaterial has good optical performance, including bright light emission in the near-infrared two-region, has good penetration capacity on biological tissues, the fluorescent detector (SWCNT-NBD) has low detection line, wide linear range, good selectivity on DA, and is convenient to prepare and low in cost.

The invention discloses a probiotic with the characteristic of high yield of bile salt hydrolase and application of the probiotic in a preparation for preventing or improving cholestatic jaundice, and is characterized in that the probiotic is at least one of a bifidobacterium longum subsp. Infantis QS033 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35879 and a lactobacillus delbrueckii subsp. Lactis QS021 strain with the preservation number of CGMCC No.35880; according to the present invention, the Chukrasone A has the application of the Chukrasone A in the preparation of the product for preventing, relieving or regulating the cholestatic jaundice, and has the advantages of effective degradation of sodium glycocholate, sodium glycodeoxycholate, sodium glycochenodeoxycholate and sodium glycoursodeoxycholate, effective regulation of bile acid metabolism disorder in the cholestatic jaundice, and improvement of the cholestatic jaundice.

The invention provides a rain wash resistant and long-acting antibacterial liquid-liquid condensed phase and a preparation method and application thereof.The liquid-liquid condensed phase comprises polyethyleneimine, sodium deoxycholate and metal chloride salt, the concentration of the polyethyleneimine is 0.5 g / L-5 g / L, and the molecular weight of the polyethyleneimine is 600-25000; the concentration of the sodium deoxycholate is 0.5 mM to 50 mM.

Disclosed are a pharmaceutical composition, an aprepitant injection, and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer, and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate and the secondary stabilizer comprises povidone. The aprepitant injection can be administered by injecting. The formulation uses a largely reduced amount of excipients, and is less irritative to an injection site, less prone to cause a hypersensitive reaction, and thus safer when being used by a patient. The formulation has good stability and can be stored and transported at room temperature, largely reducing production, storage, and transportation costs.

The application provides a kind of antibiotic-loaded nanoemulsion and its preparation method and application, it is related to the technical field of medical adjuvant, antibiotic is mixed with medicinal adjuvant soybean oil, dipalmitoyl phosphatidylcholine and cholesterol, and volatile organic solvent is used to dissolve and form oil phase;Deoxycholic acid sodium and tween are dissolved in sterile liquid to form water phase;Oil phase and water phase are mixed, and are treated by ultrasonic treatment, rotary evaporation treatment and high pressure homogenization treatment, to obtain antibiotic-loaded nanoemulsion.The application adjusts the type of inhalable medicinal adjuvant, the addition ratio of inhalable medicinal adjuvant, the ratio of oil phase and water phase, and the ultrasonic power and homogenization pressure and other factors, so that the prepared nanoemulsion can efficiently load antibiotic, and has good aerosol inhalation performance, better drug stability, the nanoemulsion can be retained in mouse lung tissue for a long time, and the lung drug delivery efficiency is significantly improved.

This invention relates to a midazolam nanocrystal suspension, which, by weight-volume percentage, comprises 5%–45% midazolam, 1%–10% Tween, and 0.1%–10% sodium deoxycholate (SDC). The midazolam nanocrystal suspension of this invention exhibits superior blood-brain barrier permeability and bioavailability, making it suitable for needle-free injection administration.

The invention relates to the technical field of medicines, and provides a semeglutide coated tablet and a preparation method thereof. The chip-coated sheet comprises a chip core layer and a shell layer, the tablet core layer comprises a first absorption enhancer; the shell layer comprises a second absorption enhancer; the first absorption enhancer and the second absorption enhancer are selected from the group consisting of sodium 8-(2-hydroxybenzamido) caprylate, Tween 80, lauryl sodium sulfate, sodium caprate, polyglycerol-3 diisostearate, oleic acid, lauric acid, sodium deoxycholate, sodium cholate, polyoxyethylene (35) castor oil, PEG-vitamin E succinate, PEG-vitamin D3 succinate and pluronic. The invention relates to a preservative which is prepared from the following raw materials: polyethylene glycol, a methoxy polyethylene glycol-polycaprolactone copolymer, sucrose fatty acid ester, 15-hydroxystearic acid polyethylene glycol ester and caprylic / capric acid polyethylene glycol glyceride. The coated tablet provided by the invention adopts a double-layer structure consisting of the tablet core layer and the shell layer, so that the bioavailability of the preparation can be remarkably improved, the oral dosage can be hopefully and greatly reduced, and the medication cost is reduced.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The invention discloses a single-walled carbon nanotube magnetic purification method and a single-walled carbon nanotube magnetic purification device. Efficient purification is realized through the synergistic effect of high-temperature oxidation and gradient magnetic field technologies. The method comprises the following steps: carrying out thermal oxidation pretreatment on a single-walled carbon nanotube in a mixed atmosphere of nitrogen and synthetic air at 450 DEG C, removing amorphous carbon and exposing metal impurities; dispersing the oxidized single-walled carbon nanotubes in a 1% sodium deoxycholate or sodium dodecyl benzene sulfonate solution; two-stage magnetic treatment is adopted, in the first stage, an N48 neodymium magnet array rotary reactor is used for removing strong magnetic impurities, and in the second stage, a nanotube aggregate is further separated through an N42 neodymium magnet annular cavity. The device comprises a reaction chamber, a magnet array and a motor system, the energy consumption is as low as 15 mW, and the metal impurity removal rate is greater than 97%. The method overcomes the defects of high energy consumption of a traditional centrifugal method and structural damage of an acidification method, is suitable for the single-walled carbon nanotubes prepared by various processes such as HiPco, CoMoCAT and the like, and has the potential of high efficiency, environmental protection and industrial application.

The invention discloses a suspension liquid. The suspension comprises brexpiprazole or a salt thereof, a suspending aid and a surfactant, wherein the surfactant is selected from the group consisting of Tween 20; and at least one of span, poloxamer, lauryl sodium sulfate and sodium deoxycholate. By adopting the surfactant, the suspension can be prevented from generating precipitates after being placed for a long time, and the particle size of the brexpiprazole or the salt of the brexpiprazole can be ensured to be within 10 microns after the brexpiprazole or the salt of the brexpiprazole is placed for one month; the suspension can be rapidly released after being injected into an animal body, achieves an effective treatment level, is continuously and slowly released to maintain the effective treatment level for 30 days or more, has good pharmacokinetic properties, and can solve the problem of patient compliance to the greatest extent. The suspension provided by the invention has the advantages of lasting drug effect, accurate particle size control, high stability, good pharmacokinetic property and the like.

The present application relates to a curcumin nanocrystal composition, the composition contains 1-18% (m / v) of curcumin nanocrystal, 0.1-10% (m / v) of stabilizer, 0.1-10% (m / v) of surfactant and 0-10% (m / v) of suspending agent in mass volume percentage, wherein the particle size of the curcumin nanocrystal is less than or equal to 100 nm, the stabilizer is selected from any one or combination of hydroxypropyl methyl cellulose (HPMC), polyvinylpyrrolidone PVPK12PF, polyvinylpyrrolidone PVPK15, polyvinylpyrrolidone PVPK17PF, lecithin, polyethylene glycol, poloxamer Pluronics F68, poloxamer Pluronics F108, the surfactant is selected from any one or combination of sodium cholate, sodium deoxycholate, sodium docusate, sodium dodecyl sulfate (SDS), sodium dodecyl sulfonate (SLS), sodium alginate, and the suspending agent is selected from any one or combination of sucrose, dextran, glycerol, povidone, hydroxypropyl cellulose, methyl cellulose, hypromellose, sodium carboxymethyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, gum arabic, dextrin. The composition of the present application has the advantages of fast onset, good stability, high bioavailability, safety and effectiveness.

The present application provides a method for separating single chiral carbon nanotube mirror bodies, comprising the following steps: (1) dispersing carbon nanotube raw materials into a solution of a composite surfactant to obtain a carbon nanotube dispersion liquid; (2) using gel chromatography for stepwise elution to separate the carbon nanotube dispersion liquid, and collecting the separation product to obtain single chiral carbon nanotube mirror bodies; wherein the solution of the composite surfactant comprises cholic acid, a first surfactant and an optional second surfactant, and a solvent; the first surfactant is selected from one or more of sodium octyl sulfate, sodium decyl sulfate, sodium dodecyl sulfate and sodium n-hexadecyl sulfate; the second surfactant is selected from one or more of sodium cholate, sodium hydrate cholate, sodium dehydrocholate, sodium deoxycholate, sodium lithocholate, sodium hyodeoxycholate and sodium chenodeoxycholate. The method of the present application can separate and prepare single chiral carbon nanotube mirror bodies with a diameter of less than 0.69 nanometers.

The present disclosure relates to a pharmaceutical composition of a JAK kinase inhibitor. Specifically, the invention provides a pharmaceutical composition, which comprises an active component (3aR, 5s, 6aS)-N-(3-methoxy-1, 2, 4-thiadiazole-5-yl)-5-(methyl (7H-pyrrolo [2, 3-d] pyrimidine-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-formamide or a pharmaceutically acceptable salt thereof, and an anionic surfactant, and the active component (3aR, 5s, 6aS)-N-(3-methoxy-1, 2, 4-thiadiazole-5-yl)-5-(methyl (7H-pyrrolo [2, 3-d] pyrimidine-4-yl) amino) hexahydrocyclopenta [c] pyrrol-2 (1H)-formamide or a pharmaceutically acceptable salt thereof, the anionic surfactant is selected from at least one of lauryl sodium sulfate and sodium deoxycholate. The pharmaceutical composition can improve the solubility of the active ingredients, the content of impurities in the finished product is low, and the pharmaceutical composition has good stability and meets the quality requirements of oral preparations.

The application discloses a kind of DOC-Chaps synergistic core's clinical and animal tissue rapid transparent reagent and three-dimensional imaging method. Rapid transparent reagent is mainly dissolved in deionized water by sodium deoxycholate (DOC), 3-[(3-cholamide propyl) dimethylamino]-1-propane sulfonic acid (Chaps), urea and 1-methylimidazole; DOC efficiently dissolves high-density lipid, Chaps gently destroys membrane structure, both complement each other, realize lipid rapid, depth clearance and significantly reduce light scattering; urea loosens collagen fiber and protein aggregate, improves the penetration rate of reagent; 1-methylimidazole selectively removes hemoglobin, reduces light absorption. The transparent reagent of the application can make millimeter thick brain slices in 4 (mouse brain) / 6 (human brain) hours The light transmittance of specific wavelength is greater than or equal to 90%, and there is no obvious tissue shrinkage / expansion, the compatibility of fluorescent protein and antibody label is excellent, suitable for three-dimensional imaging of high-lipid, high-hemoglobin samples such as in-vitro human brain, kidney, liver and mouse brain, heart, kidney, liver, intestinal tract, embryo, etc.

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

The invention relates to the technical field of medicine, in particular to an icaritin-sodium taurodeoxycholate co-amorphous substance and a preparation method and application thereof.In the icaritin-sodium taurodeoxycholate composition, icaritin serves as a main active ingredient, sodium taurodeoxycholate serves as a potential biological surfactant, and the icaritin-sodium taurodeoxycholate co-amorphous substance has the advantages that the icaritin-sodium taurodeoxycholate co-amorphous substance can be used for preparing an anti-inflammatory drug; wherein the molar ratio of icaritin to sodium taurodeoxycholate is (1: 0.5)-(1: 5), preferably (1: 1)-(1: 2). According to the icaritin-taurodeoxycholic acid sodium co-amorphous substance disclosed by the invention, the dissolving property and the dissolution property of icaritin can be remarkably improved, and the problem that the solubility and the dissolution rate of icaritin are low is solved; under the same dosage, the icaritin-sodium taurodeoxycholate co-amorphous substance has better tumor inhibition effect and oral bioavailability than icaritin.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The application provides a method for improving the linear range of a latex-enhanced turbidimetry kit and the latex-enhanced turbidimetry kit, and relates to the technical field of analysis and detection. The application finds that sodium deoxycholate is added to reagent 1 of the existing latex-enhanced turbidimetry kit. Experimental verification shows that the correlation coefficient of the existing latex-enhanced turbidimetry kit can be effectively improved, and the upper limit of the detection linearity of the latex-enhanced turbidimetry kit is improved to 500 mg / L, thereby effectively alleviating the problem that the linear range of the reagent of the existing latex-enhanced turbidimetry kit is narrow, and 90% of the sample amount in the clinic cannot be covered, so as to affect the accuracy of the clinical detection result.

The invention discloses a selective culture medium and method for screening or separating aeromonas, and relates to the technical field of microbial culture. The selective culture medium comprises a yeast extract, a nitrogen source, a carbon source, sodium citrate, sodium deoxycholate, sodium thiosulfate, ferric citrate, sodium chloride, agar, an acid-base indicator, ampicillin and diaminopteridine. The method can be used for rapidly and efficiently separating the aeromonas, and provides reliable preposition selection for detection or identification of the aeromonas.

The application discloses a pharmaceutical composition, an aprepitant injection and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate, and the secondary stabilizer comprises povidone. The aprepitant injection provided by the application can be injected for administration, the dosage of auxiliary materials is greatly reduced, the injection site is less irritating when used by patients, and the aprepitant injection is less likely to cause hypersensitivity reaction and is safer; the preparation has good stability, can be stored and transported at room temperature, and greatly reduces the production, storage and transportation costs.

The present invention discloses a polyamide reverse osmosis membrane with a high retention rate and a preparation method thereof, and relates to the field of membrane separation technology. By selecting a polyethersulfone ultrafiltration base membrane as a support layer, the basic characteristics of high mechanical strength and chemical resistance are guaranteed. By pre-treatment with sodium dodecyl sulfate solution, N,N,N-trimethyl chitosan and sodium deoxycholate, its hydrophilicity is enhanced, providing active sites for interfacial polymerization to form polyamide. By adding a surfactant to the aqueous phase solution, the diffusion rate of amine monomers in the interfacial polymerization reaction is accelerated. Modified silica is added to the oil phase solution to form a stable organosilicon graft layer on the surface of nano-silica. Tertiary butylhydroquinone is grafted on the surface of the nano-silica to reduce the attack of chlorine on the polyamide chain and improve its chlorine resistance. By regulating the surface charge of the base membrane, activating the interface, and introducing anti-chlorine groups, the retention rate of the polyamide reverse osmosis membrane for salt inorganic substances is improved.

The application discloses a metal organic framework material with a hollow structure and a preparation method and application thereof. The preparation method comprises the following steps: dissolving sodium deoxycholate in a buffer solution to form solution A, dissolving zinc nitrate hexahydrate in water to form solution B, stirring solution A in a water bath, then adding solution B to continue stirring, obtaining solution C after separation and dispersion, adding an organic ligand to solution C to react, and centrifuging, washing and drying the product to obtain the metal organic framework material with the hollow structure. The method has the advantages of simple operation, easy process control, high economy, wide popularization, fast transmission quality of the prepared MOFs material, high porosity, rich active components, more exposed active sites, good compatibility to harsh conditions, and wide application prospects in the fields of separation, sensing, catalysis, drug release and energy.

The application discloses a composition with the effect of auxiliary treatment of arthritis and a preparation method and application thereof, and the composition comprises the following preparation raw materials in parts by weight: non-denatured type II collagen 5-15 parts, curcuma longa extract 56.8-100 parts, frankincense extract 18.7-39.8 parts, sophora flower bud extract 15-28.5 parts, chondroitin sulfate 20-30 parts, glyceryl behenate 15-25 parts, chitosan 3-7.5 parts, sodium deoxycholate 3-8 parts, polyethylene glycol-15 hydroxystearate 5-15 parts, anti-knotting agent 1-3 parts, curing agent 5-15 parts and filling agent 15-25 parts. The application can treat arthritis through the trinity of immune-mechanical-metabolic pathways, and the effect is remarkable and fast, and has a certain residual effect.

The present disclosure provides methods for preparing digested virus proteins, including adenovirus and adeno-associated virus capsid proteins, from a sample of virus proteins, as well as methods of analyzing such digested virus proteins via liquid chromatography-tandem mass spectrometry. The methods include the use of a mixture of sodium deoxycholate (SDC) and N-dodecyl-beta-D-Maltoside (DDM) to rapidly and easily prepare the digested virus proteins.

This invention belongs to the field of cosmetic technology, specifically relating to an essential oil for promoting skin regeneration and its preparation method. By weight, it comprises the following components: 50-60 parts rosehip oil, 6-8 parts lavender essential oil, 8-10 parts rose essential oil, 4-6 parts modified polyaspartic acid penetration enhancer, and 1-3 parts stearyl alcohol-modified recombinant collagen flexible liposomes. In this invention, recombinant collagen is encapsulated in liposomes, and sodium deoxycholate is added during the liposome preparation process. The liposomes encapsulating the recombinant collagen deform as they pass through the intercellular channels of skin cells, adapting to the size of the intercellular channels, thereby improving the absorption of the recombinant collagen and enabling it to reach the dermis, promoting collagen production in the dermis and thus promoting skin regeneration.

A formulation for nutraceutical and / or pharmaceutical use based on protein nanoparticles is described, including a bioactive compound chosen from hydroxytyrosol, tyrosol, olive phenolic compounds, and mixtures thereof, and a zein protein matrix stabilized with sodium deoxycholate.

The invention discloses a clinical and animal tissue rapid transparentizing reagent taking DOC-Chaps cooperation as a core and a three-dimensional imaging method. The rapid transparentizing reagent is mainly prepared by dissolving sodium deoxycholate (DOC), 3-[(3-cholamidopropyl) dimethylamino]-1-propanesulfonic acid (Chaps), urea and 1-methylimidazole in deionized water; dOC efficiently dissolves high-density lipid, Chaps mildly destroys a membrane structure, and DOC and Chaps complement each other and cooperate with each other, so that rapid and deep removal of lipid is realized, and light scattering is remarkably reduced; urea loosens collagenous fibers and protein aggregates, so that the permeation rate of the reagent is increased; 1-methylimidazole is used for selectively removing heme and reducing light absorption. According to the transparent reagent, the light transmittance of a millimeter-thickness brain slice at a specific wavelength can be larger than or equal to 90% within 4 (mouse brain) / 6 (human brain) hours, no obvious tissue contraction / expansion exists, the compatibility of fluorescent protein and antibody labeling is excellent, and the transparent reagent is suitable for three-dimensional imaging of high-lipid and high-heme samples such as in-vitro human brain, kidney and liver and mouse brain, heart, kidney, liver, intestinal tract and embryo.

The application belongs to the technical field of in vitro diagnostic reagents, and discloses a cleaning solution for acridinium ester chemiluminescence immunoassay of allergens, a preparation method and application thereof. The cleaning solution is composed of HEPES buffer, a triple surfactant system (poloxamer 188, sodium deoxycholate and octyldecyl glucoside), glycerol, PEG8000, disodium EDTA and a composite preservative of Proclin 950 and BHT. The triple surfactant synergistic system is adopted to reduce non-specific adsorption, the HEPES weak alkaline buffer system avoids the inhibition of phosphates on acridinium ester luminescence, and the composite preservative system solves the toxicity and stability problems of traditional preservatives. The cleaning solution can significantly reduce the background luminescence value, the inhibition rate of hemolysis / lipemia / jaundice interference is less than 5%, the detection accuracy deviation is within ±5% (r>0.99), the precision is less than 3.5%, and the room temperature stability is more than 13 months, and the comprehensive performance is better than that of the commercially available products.

The invention provides a lipase detection kit, application and a lipase detection method. The detection kit comprises a first solvent, a second solvent and a substrate, the first solvent comprises a disodium hydrogen phosphate buffer solution, tartaric acid and sodium deoxycholate, the pH value of the first solvent is 7.0-9.0, the concentration of the disodium hydrogen phosphate buffer solution is 0.11-0.28 moL / L, and the dosage of the sodium deoxycholate is also limited; the second solvent comprises dimethyl sulfoxide; according to the present invention, the substrate is 1, 2-di-O-lauroyl-racemic-glycerol-3-(glutaric acid 6-methyl resorufin ester), and the above kit can be used for detecting lipase, can easily improve the stability of the substrate 1, 2-di-O-lauroyl-racemic-glycerol-3-(glutaric acid 6-methyl resorufin ester), can easily expose the active center of lipase, and can be used for detecting lipase. And the accuracy of a detection result is improved.